EGFR and non-small cell lung carcinoma: Various EMT signatures have been shown to predict resistance to epidermal growth factor receptor (EGFR) or phosphatidylinositol 3-kinase (PI3K) inhibitors in clinical samples and cell lines derived from non-small-cell lung cancer patients (127).